Qianjin Pharmaceutical: Subsidiary Obtains Fructose Oral Solution "Drug Registration Certificate"

Qianjin Pharmaceutical announced that its subsidiary Qianjin Xiangjiang Pharmaceutical has received the drug registration certificate for lactulose oral solution approved and issued by the National Medical Products Administration, with a specification of 200ml:133.4g and classified as chemical drug class 4. This medication is used for chronic or habitual constipation, hepatic encephalopathy, etc., with a total sales amount in the domestic medical and retail market of 2.306 billion yuan by 2025. As of the announcement date, Qianjin Xiangjiang Pharmaceutical has accumulated research and development investment of 2.9505 million yuan. This certificate enriches the company's product pipeline, but the production and sales of the drug are subject to uncertainties such as policy and market factors.